supported by the National Natural Science Foundation of China(Nos.82373169,82273412,82372704).
The potential benefit of neoadjuvant toripalimab plus axitinib in cases with clear cell renal cell carcinoma(ccRCC)and inferior vena cava tumor thrombus(IVC-TT)remains unclear.NEOTAX was a phase 2 study to investigate...
Supported by the National Natural Science Foundation of China,No.81803160.
BACKGROUND Renal clear cell carcinoma(RCC)is a malignant tumor of the genitourinary system with a predilection for males.The most common metastatic sites are the lung,liver,lymph nodes,contralateral kidney or adrenal ...
Supported by the Research and Development Program of The General Hospital of Western Theater Command,No.2021-XZYG-C04 and 2021-XZYG-C05。
BACKGROUND Renal cell carcinoma(RCC)with Xp11.2 translocation/TFE3 gene fusion is a rare and distinct subtype of RCC that is classified under tumors with translocation of the microphthalmia-associated transcriptional ...
supported by Shanghai Science and Technology Commission Research Project(21ZR1438900);the Incubating Program for Clinical Research and Innovation of Renji Hospital(PYXJS16-008,PYIII20-07).
Dear editor,The prognosis of metastatic renal cell carcinoma(mRCC)has been significantly improvedwith the development and widespread use of vascular endothelial growth factor(VEGF)pathway inhibitors and mammalian targ...
The therapeutic landscape for advanced clear cell renal cell carcinoma(ccRCC)is rapidly evolving with improved knowledge of the biology of disease leading to the incorporation of a variety of antiangiogenic agents and...
National Natural Science Foundation of China(Grant No.81473277).
Rising evidence has shown the development of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors in the practices of cancer therapy. It is reported that the efficacy of axitinib (AX), a VEGFR ...
This study was supported by the research project of Shanghai Science and Technology Commission(18ZR1423200);the Incubating Program for Clinical Research and Innovation of Renji Hospital(PYXJS16-008);the Shen Kang 3-year action plan program(16CR3062B)
Dear editor,Renal cancer accounts for approximately 2%of all can-cer deaths worldwide,and renal cell carcinoma(RCC)is the predominant subtype[1].Radiotherapy and chemo-therapy have been found to have limited roles in ...
supported by grants from the National Natural Science Foundation of China (81773554 to H. Yu);the National Natural Science Foundation of China Grant for Young Scientists (81302512 to J. Bai)
We sought to investigate safety of axitinib or sorafenib in renal cell carcinoma(RCC) patients and compare toxicity of these two vascular endothelial growth factor receptor inhibitors. Databases of PubMed and Embase...